Study identifier:D7552C00001
ClinicalTrials.gov identifier:NCT05251259
EudraCT identifier:2021-003338-35
CTIS identifier:N/A
A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of Atuliflapon Given Orally Once Daily for Twelve Weeks in Adults with Moderate to Severe Uncontrolled Asthma
asthma
Phase 2
No
Atuliflapon, Placebo
All
666
Interventional
18 Years - 80 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Sept 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Lead-in PK Cohort (Atuliflapon) Randomised participants will receive Atuliflapon | Drug: Atuliflapon Randomised participants will receive Atuliflapon Other Name: AZD5718 |
Experimental: Part 1: Atuliflapon Randomised participants will receive Atuliflapon | Drug: Atuliflapon Randomised participants will receive Atuliflapon Other Name: AZD5718 |
Placebo Comparator: Lead-in PK, Part 1 Placebo Randomised participants will receive placebo | Drug: Placebo Randomised participants will receive placebo |